Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

ASCO 2024 Glimpse ahead: Unveiling the Latest in Antibody-Drug Conjugates

Antibody-Drug Conjugates ASCO 2024 Preview

Antibody-Drug Conjugates (ADCs) are becoming increasingly prominent in the oncology landscape, representing a paradigm shift in cancer treatment. These therapies offer a targeted and potent approach, potentially enhancing patient outcomes while reducing the adverse effects often associated with traditional chemotherapy. Many large-cap companies are actively working in this space such as Roche, Seagen/Takeda, Gilead Sciences, Pfizer, GlaxoSmithKline, Daiichi Sankyo/AstraZeneca, among others. Infact, Pfizer’s USD 43 billion acquisition of Seagen in December 2022 was one of the biggest deals that ADC space had ever seen.

With over 200 ADCs in pre-clinical or clinical development, it is clear that the world is entering a new era of targeted cancer therapy. Aligned with this trend, DelveInsight has curated a list of the top 10 ADCs abstracts from ASCO 2024, each with the potential to revolutionize patient care. These abstracts promise significant advancements, aiming to positively impact the lives of patients affected by diverse forms of cancer.

Antibody-Drug Conjugates (ADCs) Key Abstracts

Company

Drug

Payload

Trial ID/ Acronym

Phase

Abstract ID

Abstract Title

Brentuximab vedotin





Monomethyl auristatin E (MMAE)

NCT04404283/

ECHELON-3

III

Oral Abstract Session - LBA7005

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

Sacituzumab tirumotecan




Belotecan-derivative topisomerase I inhibitor

NCT05347134/

OptiTROP-Breast01)

III

Clinical Science Symposium - 104

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study

Sacituzumab govitecan






SN38

NCT05089734/

EVOKE-01

III

Oral Abstract Session - LBA8500

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study

Trastuzumab deruxtecan











Topoisomerase I inhibitor

NCT04494425/ (DESTINY Breast06)

III


Oral Abstract Session - LBA1000

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

Belantamab mafodotin







Monomethyl Auristatin F (MMAF)

NCT04484623/

DREAMM 8

III

Clinical Science Symposium - LBA105

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)

Enfortumab vedotin







Monomethyl auristatin E (MMAE)

NCT04223856

III


Oral Abstract Session - 4502

Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

Brentuximab vedotin





Monomethyl auristatin E (MMAE)

NCT04569032/

SGN35-032

II

Poster Session - 52, Abstract- 7069

Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study


C:\Users\Himanshu Saxena\AppData\Local\Packages\Microsoft.Windows.Photos_8wekyb3d8bbwe\TempState\ShareServiceTempFolder\download.jpeg

Telisotuzumab vedotin






Monomethyl auristatin E (MMAE)

NCT03539536/

LUMINOSITY

II

Clinical Science Symposium - 103

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial

Tisotumab vedotin




Monomethyl auristatin E (MMAE)

NCT03485209

II

Rapid Oral Abstract Session - 6012

Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C


C:\Users\Himanshu Saxena\AppData\Local\Packages\Microsoft.Windows.Photos_8wekyb3d8bbwe\TempState\ShareServiceTempFolder\download.jpeg

ABBV-400




Topoisomerase I inhibitor

NCT05029882

I

Rapid Oral Abstract Session - 3515

First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer

Tags:

Executive Summary

With over 200 ADCs in pre-clinical or clinical development, it is clear that the world is entering a new era of targeted cancer therapy.

Recent Articles